Alzheimer's disease is characterized by the accumulation of two proteins in the brain: amyloid-beta and tau. Tau normally ...

Amyloid beta and tau proteins compete for the same binding sites on microtubules in neurons, suggesting that displacement of ...

NEWTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid ...

Research from UC Santa Cruz indicates that the P3 peptide—an alternative cleavage product of the amyloid precursor ...

Findings underpin potential of Anavex’ lead candidate blarcamesine through its upstream mechanism of action and SIGMAR1-mediated autophagy restorationNEW YORK, March 20, 2026 (GLOBE NEWSWIRE) -- ...

Science rarely hands us plot twists this dramatic—where two of the most feared diseases of our time, cancer and Alzheimer’s, ...

Alzheimer's disease (AD) is a neurodegenerative disease that causes progressive memory loss and a significant decline in ...

Novel and potent catalytic approach that directly clears amyloid on the inside of neurons as well as reduces amyloid plaques with the potential ...

At first glance, it might appear that better access to so-called amyloid-PET scans could compensate for some of the racial inequities in Alzheimer’s disease, as Linda Goler Blount called for in a ...

Transthyretin amyloidosis (ATTR) is a rare, progressive and highly aggressive degenerative disease. It is caused by the misfolding of a specific protein, leading to its toxic accumulation in the form ...